Strategic funding Leverage ADMdx’s recent NIH and grant funding of nearly $2M to approach potential partners for joint development of diagnostic tests and imaging analysis services, highlighting financial backing and validation for expansion into clinical tools.

Clinical partnerships Target pharmaceutical companies and academic centers seeking centralized imaging acquisition and analysis to support trials, by offering ADMdx’s brain image analytics as a scalable, outsourced service that differentiates assessments of cognitive decline and drug effects.

Differentiated diagnostics Position ADMdx’s ability to differentiate dementia types, predict cognitive decline, and detect drug effects as a unique value proposition for researchers and clinicians aiming to improve trial endpoints and early diagnosis workflows.

Small team agility Emphasize the compact, nimble team as a selling point for rapid onboarding and custom solutions, while addressing potential scalability needs with partner-ready, cloud-enabled data processing and outsourcing capabilities.

Growth opportunities Explore expansions into diagnostic support tools for clinics and broader imaging services for pharma, leveraging existing tech stack and partnerships to upsell data analysis, imaging acquisition, and regulatory-compliant reporting.